EAPI.PA

Bargain Bin

Euroapi S.A. · Healthcare · France · $67M cap · $133K/day traded

EUR 0.642 -5.9% · close 20 Nov · scored 21 Nov

Bargain Bin: Looks like a bargain; the quality and the trend say why it is in the bin.

44
Score
Get score and insider alerts
Quality
37
Value
77
Momentum
24

As of 21 Nov 2026, the MoatMap Score for Euroapi S.A. (EAPI.PA) is 44/100, ranked against 25,000+ stocks in 38 markets (Quality 37, Value 77, Momentum 24, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
—
peers 23.2x
ROE
-40.0%
peers -69.7%
D/E
0.2x
peers 0.7x
Dividend %
—
trailing yield

ABOUT EUROAPI S.A.

Read

Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.

FINANCIAL SUMMARY (EUR)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue980.9M1.0B919.2M852.6M-4.6%794.6M752.2M751.5M-6.1%
Net margin-1.5%-18.6%-14.2%-24.8%-23.3 pts————
EPS (EUR)-0.2-2.0-1.4-2.2—-3.2———
Share count94.0M94.8M95.2M95.2M0.4%95.5M———
Balance sheet
Debt120.8M225.5M69.1M65.4M-18.5%109.0M———
Equity1.1B927.8M983.6M788.2M-10.8%————
Debt/equity0.1x0.2x0.1x0.1x0.0x————
Cash flow
Op. cash flow44.8M5.1M122.9M128.5M42.1%45.8M———
Cash flow margin4.6%0.5%13.4%15.1%+10.5 pts5.8%———
Investing CF-167.4M-137.3M-108.0M-77.0M—————
Financing CF187.8M92.2M26.5M-13.3M—————
PRICE (1Y) · EUR-16.8%
0.640.690.730.780.8212 Oct2 Nov20 Nov
SMA 50SMA 200

Price checkStill fallingExperimental

Made a new 52-week low in the latest session, 80% below its 52-week high. The fall has not stopped yet.

SwingsBumpy

Swung more than 67% of stocks we rank over the past year (volatility 54% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling (this stock): It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
EUR 0.642
RSI (14)
17.3
52-Week Range-80.1% from high
Low EUR 0.629High EUR 3.22

SCORE BREAKDOWN

Quality
37
ROIC
-12.9%32.3
ROE
-40.0%20.7
GP/Assets
9.3%24.8
Op. Margin
-2.5%31.7
FCF/Assets
3.8%63.2
Piotroski
549.5
Int. Cover
-16.9x18.2
D/E Ratio
0.16x54.0
Current Ratio
2.01x39.9
Value
77
P/E (TTM)
—N/A
EV/EBITDA
0.9x98.6
P/FCF
1.2x99.3
P/B
0.1x99.8
P/S
0.1x99.4
Div Yield
—N/A
Momentum
24
52W High %
20%6.6
RS 6M
-54%6.1
SMA 50/200
0.65x7.1
EPS Rev 4W
0.0%46.7
EPS Rev 12W
—N/A
EPS Improve
+93%73.8
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$67M
P/E (Forward)
-3.0x
Gross Margin
15.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EAPI.PA are excluded.

TickerCompanyMkt CapScore
EAPI.PAEuroapi S.A.(you)$67M44
AB.PAAB Science S.A.$55M5
BOI.PABoiron SA$359M89
VETO.PAVetoquinol SA$1.1B95
GBT.PAGuerbet SA$90M32
NCYT.LNovacyt S.A.$34M33
ALGAE.PAFermentalg SA$51M15
ALTHE.PATheraclion SA$50M11
ALSEN.PASensorion SA$80M8
ALCJ.PACrossject Société Anonyme$86M6

Peer medians: ROE -69.7% · P/E 23.2x · Gross margin 69.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Euroapi S.A. (EAPI.PA): Stock Score Summary

Euroapi S.A. (EAPI.PA) has a MoatMap Score of 44/100 based on Quality (37/100), Value (77/100), and Momentum (24/100) factor scores.

Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.

Director dealings

From 19 Feb 2026 to 20 Nov 2026, MoatMap's records hold no purchases or sales of Euroapi S.A. (EAPI.PA) shares by its directors.

EAPI.PA insider filings, last 180 days

Key Financial Metrics

PriceEUR 0.642
Market Cap$67M
P/E (Forward)-3.00
Price/Book0.13
Return on Equity-40.0%
Return on Invested Capital-12.9%
Debt/Equity0.16x
Gross Margin15.6%
Operating Margin-2.5%
Revenue Growth-14.0%
Free Cash Flow$56M

Euroapi S.A. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (France).

Frequently Asked Questions

What is Euroapi S.A.’s (EAPI.PA) MoatMap Score?
The MoatMap Score for Euroapi S.A. (EAPI.PA) is 44/100. It is a composite of Quality (37), Value (77), and Momentum (24), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Euroapi S.A. have an economic moat?
Euroapi S.A. (EAPI.PA) has a Quality factor score of 37/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Euroapi S.A. in?
Euroapi S.A. (EAPI.PA) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (France).